The effects of calcium channel blockers on nuclear factor kappa B activation in the mesangium cells

被引:38
作者
Hayashi, M [1 ]
Yamaji, Y [1 ]
Nakazato, Y [1 ]
Saruta, T [1 ]
机构
[1] Keio Univ, Sch Med, Dept Internal Med, Shinjuku Ku, Tokyo 1608582, Japan
关键词
calcium channel blockers; mesangium cells; nuclear factor kappa B;
D O I
10.1291/hypres.23.521
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
It has been reported that calcium channel blockers (CCBs) have an inhibitory action on cell growth and transcriptional changes induced by cytokines and hormones, In this study, we examined the effects of CCBs on nuclear factor kappa B (NF kappa B), which plays a key role in the intracellular signaling of various growth factors and cytokines. The activity of NF kappa B was determined by luciferase assay with the transfection of the reporter gene, which has six NF kappa B-recognizing sequences in the upstream of herpes simplex Virus thymidine kinase promoter, In cultured human mesangial cells, increased intracellular calcium concentration by calcium ionophore, A23187, showed a stimulatory effect on the phorbor 12-myristate 18-acetate (PMA)-induced activation of NF kappa B, while L-type calcium channel agonist, Bay K 8644, did not have any significant effects on either basal or PMA-stimulated activity of NF kappa B, At a higher concentration (10 mu M), nifedipine, verapamil, or efonidipine showed an inhibitory effect on the activation of NF kappa B by PMA and A23187, while at a lower concentration (1 mu M), only efonidipine showed a significant inhibitory effect. From these results, we conclude that CCBs have an inhibitory effect on NF kappa B via the independent pathway of an L-type calcium channel and that the potency of this effect is variable among L-type calcium channel blockers.
引用
收藏
页码:521 / 525
页数:5
相关论文
共 19 条
[1]  
BAUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141
[2]   A DOMINANT-NEGATIVE PROTEIN-KINASE-C ZETA-SUBSPECIES BLOCKS NF-KAPPA-B ACTIVATION [J].
DIAZMECO, MT ;
BERRA, E ;
MUNICIO, MM ;
SANZ, L ;
LOZANO, J ;
DOMINGUEZ, I ;
DIAZGOLPE, V ;
DELERA, MTL ;
ALCAMI, J ;
PAYA, CV ;
ARENZANASEISDEDOS, F ;
VIRELIZIER, JL ;
MOSCAT, J .
MOLECULAR AND CELLULAR BIOLOGY, 1993, 13 (08) :4770-4775
[3]  
DUQUE I, 1993, J PHARMACOL EXP THER, V267, P612
[4]   Calcium channel blockers activate the interleukin-6 gene via the transcription factors NF-IL6 and NF-κB in primary human vascular smooth muscle cells [J].
Eickelberg, O ;
Roth, M ;
Mussmann, R ;
Rüdiger, JJ ;
Tamm, M ;
Perruchoud, AP ;
Block, LH .
CIRCULATION, 1999, 99 (17) :2276-2282
[5]  
Hayashi K, 1996, Hypertens Res, V19, P31, DOI 10.1291/hypres.19.31
[6]  
HAYASHI K, 1998, CALCIUM ANTAGONISTS, P393
[7]   Antihypertensive treatment of patients with proteinuric renal diseases: Risks or benefits of calcium channel blockers? [J].
Kloke, HJ ;
Branten, AJ ;
Huysmans, FT ;
Wetzels, JF .
KIDNEY INTERNATIONAL, 1998, 53 (06) :1559-1573
[8]  
Lallena MJ, 1999, MOL CELL BIOL, V19, P2180
[9]   Interleukin (IL)-1 and IL-4 synergistically stimulate NF-IL6 activity and IL-6 production in human mesangial cells [J].
Nakazato, Y ;
Hayashida, T ;
Kanno, Y ;
Sasamura, H ;
Okada, H ;
Suzuki, H ;
Saruta, T .
KIDNEY INTERNATIONAL, 1998, 54 (01) :71-79
[10]  
Nargeot J, 1997, EUR HEART J, V18, pA15